RxDoctor Payments DataLook up a doctor →

Kristina James

Family · Gainesville, GANPI 1912452061

Payments from drug & device makers

$16,269in general payments, 2019–2025

Across 724 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$1K
  • Pfizer$1K
  • Neurelis, Inc.$748
  • MDD US Operations, LLC$638
  • Neurocrine Biosciences, Inc.$590
  • plus $10K from 48 others

What the payments were for

  • Food & beverage$16,269100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,269 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$131,696
Medicare patients
264
Services billed
14,474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab14$764,666
IngrezzaValbenazine Tosylate19$157,188
Nurtec OdtRimegepant Sulfate89$121,273
Gamunex-CImmune Globul G/Gly/Iga Avg 4614$99,102
KeppraLevetiracetam45$82,098
UbrelvyUbrogepant38$56,074
FycompaPerampanel31$48,639
AptiomEslicarbazepine Acetate14$34,945
BriviactBrivaracetam22$32,947
NayzilamMidazolam29$30,241
LamictalLamotrigine29$26,564
QuliptaAtogepant18$20,917
Rivastigmine45$10,044
Lacosamide52$8,699
Levetiracetam182$7,976

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$521$764,66614 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$590$164,34030 claims
PfizerNurtec Odt$1,079$121,27389 claims
Grifols USA, LLCGamunex-C$153$99,10214 claims
AbbVieUbrelvy, Qulipta$2,361$76,99156 claims
UCB, Inc.Briviact, Nayzilam$1,175$63,18851 claims
Eisai Inc.Fycompa$482$48,63931 claims
Sunovion Pharmaceuticals Inc.Aptiom$148$34,94514 claims
Upsher-smith Laboratories LLCTopiramate$114$3,019196 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$265$2,02532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →